Local view for "http://wifo5-04.informatik.uni-mannheim.de/drugbank/resource/drugs/DB08895"

PredicateValue (sorted: none)
drugbank:interactsWith
owl:sameAs
owl:sameAs
owl:sameAs
drugbank:interactsWith
owl:sameAs
drugbank:interactsWith
owl:sameAs
owl:sameAs
owl:sameAs
drugbank:interactsWith
drugbank:interactsWith
drugbank:interactsWith
owl:sameAs
drugbank:interactsWith
drugbank:description
"Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signaling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and the treatment of psoriasis and ulcerative colitis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz. "
owl:sameAs
owl:sameAs
owl:sameAs
owl:sameAs
owl:sameAs
drugbank:interactsWith
drugbank:interactsWith
owl:sameAs
owl:sameAs
drugbank:interactsWith
drugbank:interactsWith
owl:sameAs
drugbank:interactsWith
owl:sameAs
owl:sameAs
drugbank:interactsWith
drugbank:interactsWith
owl:sameAs
drugbank:interactsWith
owl:sameAs
owl:sameAs
drugbank:interactsWith
owl:sameAs
drugbank:interactsWith
owl:sameAs
drugbank:interactsWith
drugbank:interactsWith
rdf:type
owl:sameAs
rdfs:label
"Tofacitinib"
drugbank:interactsWith
drugbank:interactsWith
drugbank:interactsWith
owl:sameAs
owl:sameAs
drugbank:interactsWith
drugbank:interactsWith
drugbank:interactsWith
drugbank:interactsWith
drugbank:interactsWith
drugbank:interactsWith
owl:sameAs
owl:sameAs
owl:sameAs

All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines3/drugbank_small.nt

The resource appears as object in 56 triples

Context graph